mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology

Anna Jeong, Michael Wong*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


The mammalian/mechanistic target of rapamycin (mTOR) pathway is a key signaling pathway that has been implicated in genetic epilepsy syndromes, neurodegenerative diseases, and conditions associated with autism spectrum disorder and cognitive impairment. The mTOR pathway has become an exciting treatment target for these various disorders, with mTOR inhibitors such as rapamycin being studied for their potential therapeutic applications. In particular, tuberous sclerosis complex (TSC) is a genetic disorder resulting from overactivation of the mTOR pathway, and pharmacologic therapy with mTOR inhibitors has emerged as a viable treatment option for the systemic manifestations of the disease. In this review, we discuss the approved indications for mTOR inhibitors in TSC, the potential future applications of mTOR inhibitors in TSC and other neurological conditions, and the safety considerations applicable to mTOR therapy in the pediatric population.

Original languageEnglish (US)
Article number102
JournalCurrent neurology and neuroscience reports
Issue number12
StatePublished - Dec 1 2016


  • Everolimus
  • Rapamycin
  • Sirolimus
  • Tuberous sclerosis
  • mTOR

ASJC Scopus subject areas

  • Clinical Neurology
  • General Neuroscience


Dive into the research topics of 'mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology'. Together they form a unique fingerprint.

Cite this